PUBLIC COMPANY
saveREGENERON PHARMACEUTICALS
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- phase3A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- phase1A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
- phase1Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
- phase3Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
- phase2A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
- phase2A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
- phase3Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
🐶 Hiring Signal
News
- 7 companies hiring in North Carolina nowLooking for a biopharma job in North Carolina? Job postings in the area have increased. Here are seven companies with open roles.biospace · 2d ago
- Regeneron backs $75M series A for antibody upstart InfinimmuneInfinimmune has amassed further fuel to power its antibody discovery engine, netting a $75 million series A headlined by Regeneron’s venture arm.fiercebiotech · 4d ago
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 9d ago
- A COPD drug from China draws $115M in venture fundingExpedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.biopharma_dive · 10d ago
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.biopharma_dive · 14d ago
- Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chestCalls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.biospace · 15d ago
- 7 companies hiring in New York nowLooking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.biospace · 16d ago
- 6 companies hiring in Cambridge nowLooking for a biopharma job in Cambridge? Roles posted on BioSpace have more than doubled compared to last year.biospace · 23d ago
- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.biopharma_dive · 1mo ago
- Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot programThe planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.biopharma_dive · 1mo ago
comments(0)
5-min edit window · permanent after that